ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
124.718,07
0,65%
S&P 500
5.475,09
0,27%
US Dollar vs BRL
5,6568
0,00%
Bitcoin
62.568,88
-0,45%
Brent Oil
86,685
0,18%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Checkmate Pharmaceuticals Inc (CMPI)

  7. Checkmate Pharmaceuticals Inc (CMPI) Notícias

CMPI

Checkmate Pharmaceuticals (CMPI)

Checkmate Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CMPI
DataHoraFonteTítuloCódigoCompanhia
10/06/202209:37Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(b) (15-12b)NASDAQ:CMPICheckmate Pharmaceuticals Inc
07/06/202212:40Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:CMPICheckmate Pharmaceuticals Inc
03/06/202212:42Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202211:15Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202210:27Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202210:25Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202210:17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202210:13Edgar (US Regulatory)Amended Statement of Ownership: Solicitation (sc 14d9/a)NASDAQ:CMPICheckmate Pharmaceuticals Inc
31/05/202209:38Edgar (US Regulatory)Amended Tender Offer Statement by Third Party (sc To-t/a)NASDAQ:CMPICheckmate Pharmaceuticals Inc
26/05/202218:01GlobeNewswire Inc.University of Iowa Holden Comprehensive Cancer Center Presents Preliminary Data from Clinical Trial of Vidutolimod at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CMPICheckmate Pharmaceuticals Inc
12/05/202217:50Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CMPICheckmate Pharmaceuticals Inc
12/05/202217:30GlobeNewswire Inc.Checkmate Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:CMPICheckmate Pharmaceuticals Inc
05/05/202217:23Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CMPICheckmate Pharmaceuticals Inc
02/05/202210:17Edgar (US Regulatory)Statement of Ownership: Solicitation (sc 14d9)NASDAQ:CMPICheckmate Pharmaceuticals Inc
02/05/202208:49Edgar (US Regulatory)Tender Offer Statement by Third Party (sc To-t)NASDAQ:CMPICheckmate Pharmaceuticals Inc
29/04/202217:13Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:CMPICheckmate Pharmaceuticals Inc
20/04/202207:02Edgar (US Regulatory)Written Communication by the Subject Company Relating to a Third Party Tender Offer (sc14d9c)NASDAQ:CMPICheckmate Pharmaceuticals Inc
20/04/202200:45TipRanksAnalysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM) and Checkmate Pharmaceuticals (CMPI)NASDAQ:CMPICheckmate Pharmaceuticals Inc
19/04/202217:51Edgar (US Regulatory)Written Communication Relating to an Issuer or Third Party (sc To-c)NASDAQ:CMPICheckmate Pharmaceuticals Inc
19/04/202210:46Dow Jones NewsCheckmate Pharmaceuticals Shares Take Flight on Regeneron DealNASDAQ:CMPICheckmate Pharmaceuticals Inc
19/04/202208:47Dow Jones NewsRegeneron to Buy Checkmate Pharmaceuticals for About $250 MillionNASDAQ:CMPICheckmate Pharmaceuticals Inc
19/04/202208:00PR Newswire (US)Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor TypesNASDAQ:CMPICheckmate Pharmaceuticals Inc
12/04/202200:15TipRanksCheckmate Pharmaceuticals (CMPI) Receives a Buy from BTIGNASDAQ:CMPICheckmate Pharmaceuticals Inc
08/04/202214:01GlobeNewswire Inc.Checkmate Pharmaceuticals Presents Clinical Trial Biomarker Data with Vidutolimod at the 2022 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:CMPICheckmate Pharmaceuticals Inc
30/03/202208:22Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:CMPICheckmate Pharmaceuticals Inc
30/03/202200:06TipRanksAnalysts’ Top Healthcare Picks: Aldeyra Therapeutics (ALDX), Axsome Therapeutics (AXSM)NASDAQ:CMPICheckmate Pharmaceuticals Inc
29/03/202217:30GlobeNewswire Inc.Checkmate Pharmaceuticals Announces Full Year 2021 Financial Results and Provides Business UpdateNASDAQ:CMPICheckmate Pharmaceuticals Inc
08/03/202218:30GlobeNewswire Inc.Checkmate Pharmaceuticals to Present at the 2022 American Association for Cancer Research (AACR) Annual MeetingNASDAQ:CMPICheckmate Pharmaceuticals Inc
02/03/202218:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CMPICheckmate Pharmaceuticals Inc
14/02/202213:57Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CMPICheckmate Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CMPI

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
COGN3
COGNA ON
BOV
AMER3
Americanas ON
BOV
RNEW4
RENOVA PN
BOV
AMBP3
Ambipar Participacoes e ... ON
BOV
HAGA3
HAGA ON
BOV
BRKM5
BRASKEM PNA
BOV
HOOT4
HOTEIS OTHON PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados